Overcoming severe adverse reactions to venom immunotherapy using anti‐Ig<scp>E</scp> antibodies in combination with a high maintenance dose

Stretz, E.; Oppel, Eva; Räwer, Helen-Caroline; Châtelain, R; Mastnik, Sebastian; Przybilla, Bernhard; Ruëff, Franziska

doi:10.1111/cea.12997

Cited by 38 publications

(26 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the ability of omalizumab to detach prebound IgE from their receptors opens the way to additional applications in those clinical conditions in which degranulation of basophils and mast cells must be limited to prevent anaphylaxis. In this direction, it is not surprising that omalizumab works fine in mastocytosis , allergen immunotherapy , drug desensitization , and may be a promising option also for idiopathic nonhistaminergic acquired angioedema .…”

Section: Chronic Spontaneous Urticariamentioning

confidence: 99%

Biologicals targeting type 2 immunity: Lessons learned from asthma, chronic urticaria and atopic dermatitis

et al. 2019

View full text Add to dashboard Cite

During the last decades, progression of research has led to great achievements for treatment and therapy of several disabling disorders, particularly in the field of chronic inflammatory diseases. The increased knowledge of the molecular mechanisms operating in such diseases has represented the first step in this process, and the discovery of molecules able to interfere with the natural history of the diseases, has been the second. This review is focused on the effects of biologics on type 2 diseases such as asthma, chronic urticaria and atopic dermatitis, both biologics just approved for clinical application and also those that are currently undergoing clinical trials. We will also discuss aspects and emphasize clinical trials and recently published studies, as well as research that is currently in the progress, which will be highly relevant for basic immunologists. Likewise, we will cover aspects that are pertinent for clinical immunologists and highlight translational studies that are evaluating novel biologicals in animal models.Keywords: atopic dermatitis r bronchial asthma r chronic urticaria r precision medicine

show abstract

Section: Chronic Spontaneous Urticariamentioning

confidence: 99%

Biologicals targeting type 2 immunity: Lessons learned from asthma, chronic urticaria and atopic dermatitis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…While there have been no randomized controlled trials evaluating the addition of omalizumab to venom IT, several case reports and small patient series have been published on the use of omalizumab with venom IT, using a variety of treatment protocols with regard to both venom IT and omalizumab dosing . While some case reports have not shown benefit, most have suggested that the addition of pre‐treatment and/or maintenance omalizumab decreased the risk of systemic reactions during venom IT in high‐risk patients, including some individuals with mastocytosis …”

Section: Venom Immunotherapy + Omalizumabmentioning

confidence: 99%

“…While there have been no randomized controlled trials evaluating the addition of omalizumab to venom IT, several case reports and small patient series have been published on the use of omalizumab with venom IT, using a variety of treatment protocols with regard to both venom IT and omalizumab dosing. [43][44][45][46][47][48][49][50] While some case reports have not shown benefit, 49 26 In the 1990s, subcutaneous immunotherapy for peanut allergy was attempted, but had an unacceptably high rate of systemic reactions. 26,53,54 Subsequent approaches have therefore focused on different routes of delivery (oral, sublingual and epicutaneous) or modification of the allergens to reduce risk but still achieve desensitization.…”

Section: Summary and Clinical Implications Of Inhalant Allergen Immmentioning

confidence: 99%

The use of omalizumab in allergen immunotherapy

Dantzer

Wood

2018

Clin Experimental Allergy

View full text Add to dashboard Cite

Although omalizumab (anti-IgE) is currently only approved for the treatment of asthma and chronic idiopathic urticaria, it has also been studied as an off-label treatment for numerous allergic conditions, including use as an adjunct to allergen immunotherapy in the treatment of allergic rhinitis, asthma, venom hypersensitivity and food allergy. We conducted a review of publications involving the use of omalizumab with allergen immunotherapy, by searching PubMed with key search terms of "omalizumab" and "immunotherapy." Omalizumab has been used in combination with inhalant allergen immunotherapy for the treatment of seasonal allergic rhinitis and comorbid asthma. While there have been no randomized controlled trials evaluating the addition of omalizumab to venom IT, several case reports and small patient series have been published on the use of omalizumab with venom IT. Omalizumab has been used in conjunction with oral immunotherapy for the treatment of milk, peanut and egg, as well as other foods in multi-allergen protocols. In conclusion, omalizumab used in conjunction with immunotherapy has shown promising results, especially in the reduction of adverse reactions. At this stage, larger, randomized, placebo-controlled trials are needed to better identify those patients who would benefit the most from the addition of omalizumab to immunotherapy, as well as optimal dosing strategies and duration of treatment.

show abstract

“…32 Their retrospective, observational case series with 10 patients on combination therapy and five just on immunotherapy suggested that a short course of omalizumab is very helpful in this group. 32 Their retrospective, observational case series with 10 patients on combination therapy and five just on immunotherapy suggested that a short course of omalizumab is very helpful in this group.…”

Section: Anaphylaxismentioning

confidence: 99%

“…Finally, Stretz and colleagues looked at whether temporary omalizumab co-treatment with high maintenance venom dose can prevent recurrent systemic allergic reactions with venom immunotherapy. 32 Their retrospective, observational case series with 10 patients on combination therapy and five just on immunotherapy suggested that a short course of omalizumab is very helpful in this group.…”

Section: Anaphylaxismentioning

confidence: 99%

Developments in the field of allergy in 2017 through the eyes of Clinical and Experimental Allergy

Roberts

Almqvist

Boyle

et al. 2018

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

Overcoming severe adverse reactions to venom immunotherapy using anti‐IgE antibodies in combination with a high maintenance dose

Abstract: Combining a temporary omalizumab therapy with an elevated maintenance dose seems a promising approach to achieve a tolerance of treatment in patients with a recurrent SAR to VIT.

Cited by 38 publications

References 22 publications

Biologicals targeting type 2 immunity: Lessons learned from asthma, chronic urticaria and atopic dermatitis

Biologicals targeting type 2 immunity: Lessons learned from asthma, chronic urticaria and atopic dermatitis

The use of omalizumab in allergen immunotherapy

Developments in the field of allergy in 2017 through the eyes of Clinical and Experimental Allergy

Contact Info

Product

Resources

About